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1. INTRODUCTION 
 
1.1 ORAL CONTROLLED DRUG DELIVERY SYSTEMS1,2  
 
Oral drug delivery is the most widely utilized route of administration among all the 
routes that have been explored for systemic delivery of drugs. Oral route is considered most 
natural, uncomplicated, convenient and safe due to its ease of administration, patient 
acceptance and cost effective manufacturing process. 
 
Pharmaceutical products designed for oral delivery are mainly conventional drug 
delivery systems, which are designed for immediate release of drug for rapid absorption. 
These immediate release dosage forms have some limitations such as:  
 
1. Drugs with short half-life require frequent administration leading to poor patient 
compliance.  
2. A typical peak-valley plasma concentration-time profile is obtained, which makes 
attainment of steady state condition difficult.  
3. The unavoidable fluctuations in the drug concentration.  
 
In order to overcome these drawbacks of conventional drug delivery systems, 
several technical advancements have led to the development of controlled drug delivery 
system that could revolutionize method of medication and provide a number of therapeutic 
benefits.
1, 2  
Controlled release drug delivery systems are more preferred over conventional drug 
delivery systems, since they are associated with several advantages like:  
 
1. Reduced dosing frequency.  
2. Reduced fluctuation in plasma drug levels.  
3. Increased patient compliance.  
4. Maximum utilization of drug.  
5. Minimal local and systemic side effects.  
6. Reduced health care costs.  
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However these systems are marked by several disadvantages like:  
1. Dose dumping.  
2. Reduced potential for accurate dose adjustment.  
3. Need for additional patient education.  
4. Possible reduction in systemic availability.  
5. Does not permit to termination of therapy in emergency.  
6. Stability problems.  
 
Oral controlled release drug delivery is a drug delivery system that provides 
continuous oral delivery of drugs at predictable and reproducible kinetics for a 
predetermined period throughout the course of GI transit. All the pharmaceutical products 
formulated for systemic delivery via the oral route of administration, irrespective of the 
mode of delivery (immediate, sustained or controlled release) and the design of dosage form 
(solid, dispersion or liquid), must be developed within the intrinsic characteristics of GI 
physiology. Therefore the scientific framework required for the successful development of 
oral drug delivery systems consists of basic understanding of (i) physicochemical, 
pharmacokinetic and pharmacodynamic characteristics of the drug (ii) the anatomic and 
physiologic characteristics of the GI tract and (iii) physicochemical characteristics and the 
drug delivery mode of the dosage form to be designed.
1  
 
Amongst the various oral controlled drug delivery systems mucoadhesive 
microspheres have generated much interest among researchers around the world. The 
microspheres offer number of benefits including reducing stress resulting from restraint, 
stability, handling and dosing, avoiding expensive and difficult drug administration 
procedures.  
 
1.2 MUCOADHESIVE DRUG DELIVERY SYSTEMS 
3 
1.2.1 Definition  
The term “mucoadhesion” was coined for the adhesion of the polymers with the 
surface of the mucosal layer. Bioadhesion is a phenomenon in which two materials at least 
one of which is biological and are held together by means of interfacial forces. 
Mucoadhesion is defined as the attachment of synthetic or biological macromolecules to the 
biological surface, which can be epithelial tissue or the mucus coat on the surface of tissue.
3
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1.2.2 Advantages  
Mucoadhesive drug delivery systems have three distinct advantages when compared 
to conventional dosage forms.  
1. The mucoadhesive systems, which are readily localized in the applied region can 
enhance or improve the bioavailability of drugs.  
2. These dosage forms can facilitate the intimate contact with underlying absorption 
surface resulting in a better absorption.  
3. They can prolong residence time at the site of application to permit once or twice a 
day dosing.  
 
1.3 MECHANISM OF MUCOADHESION 
4 
 
A General Mechanism of Mucoadhesive Drug Delivery system is show in Figure 1 
 
 
Figure 1- Mechanism of Mucoadhesion 
 
Certain theories have been proposed to explain the fundamentals of adhesion, 
 
1.3.1 Electronic theory
5 
According to this theory, electron transfers occur upon contact of adhesive polymer 
with a mucus glycoprotein network because of difference in their electronic structures. This 
results in the formation of electrical double layer at the interface e.g. Interaction between 
positively charged polymers chitosan and negatively charged mucosal surface which 
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becomes adhesive on hydration and provides an intimate contact between a dosage form 
and absorbing tissue. 
 
1.3.2 Absorption theory
 
According to this theory, after an initial contact between two surfaces, the material 
adheres because of surface force acting between the atoms in two surfaces. Two types of 
chemical bonds resulting from these forces can be distinguished as primary chemical bonds 
of covalent nature and secondary chemical bonds having many different forces of attraction, 
including electrostatic forces, Vanderwals forces, hydrogen and hydrophobic bonds. 
 
1.3.3 Diffusion theory 
According to this theory, the polymer chains and the mucus mix to a sufficient depth 
to create a semi permanent adhesive bond. The exact depth to which the polymer chain 
penetrates the mucus depends on the diffusion coefficient and the time of contact. The 
diffusion coefficient in terms depends on the value of molecular weight between 
crosslinking and decreases significantly as the cross linking density increases. 
 
1.3.4 Wetting theory 
The wetting theory postulates that if the contact angle of liquids on the substrate 
surface is lower, then there is a greater affinity for the liquid to the substrate surface. If two 
substrate surfaces are brought in contact with each other in the presence of the liquid, the 
liquid may act as an adhesive among the substrate surface. 
 
1.3.5 Cohesive theory 
The cohesive theory proposes that the phenomena of bioadhesion are mainly due to 
intermolecular interaction amongst like molecule. Based upon the above theories, the 
process of bioadhesion can broadly be classified into two categories namely chemical 
(electron and absorption theory) and physical (wetting, diffusion and cohesive theory). 
 
1.4 POLYMERS USED IN MUCOADHESIVE DRUG DELIVERY SYSTEMS
5 
Mucoadhesive polymers are water soluble as well as water insoluble polymers, 
which are swellable networks, joined by cross-linking agents. These polymers possess 
optimal polarity to make sure that they permit sufficient wetting by the mucus and optimal 
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fluidity that permits the mutual adsorption and interpenetration of polymer and mucus to 
take place. Mucoadhesive polymers that adhere to the mucin-epithelial surface can be 
conveniently divided into three broad classes. 
 
1. Polymers that become sticky when placed in water and owe their mucoadhesion to 
stickiness.  
2. Polymers that adhere through hydrogen and hydrophobic bonding interactions.  
3. Polymers that bind to specific receptor site.  
 
1.4.1Characteristics of Mucoadhesive Polymer 
  
The following characteristics are believed to be essential for exhibiting the good 
Mucoadhesive properties:  
 
(1) Strong hydrogen bonding groups, 
(2) Strong anionic charges, 
(3) High molecular weight, 
(4) Sufficient chain flexibility and  
(5) Surface energy properties favoring spreading onto mucus.
 
 
1.4.2 Hydrophilic polymers 
The polymers within this category are soluble in water. Matrices developed with 
these polymers swell when put into an aqueous media with subsequent dissolution of the 
matrix. The polyelectrolytes extend greater mucoadhesive property when compared with 
neutral polymers. Anionic polyelectrolytes, e.g. poly (acrylic acid) and carboxymethyl 
cellulose have been extensively used for designing mucoadhesive delivery systems due to 
their ability to exhibit strong hydrogen bonding with the mucin present in the mucosal layer. 
Gelatin, chitosan provides an excellent example of cationic polyelectrolyte, which has been 
extensively used for developing mucoadhesive polymer due to its good biocompatibility 
and biodegradable properties.  
 
1.4.3 Hydrogels 
Hydrogels can be defined as three-dimensionally cross linked polymer chains which 
have the ability to hold water within its porous structure. The water holding capacity of the 
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hydrogels is mainly due to the presence of hydrophilic functional groups like hydroxyl, 
amino and carboxyl groups. Hydrogels prepared by the condensation reaction of poly 
(acrylic acid) and sucrose indicated an increase in the mucoadhesive property with the 
increase in the cross linking density and was attributed to increase in the poly (acrylic acid) 
chain density per unit area.  
Acrylates have been used to develop mucoadhesive delivery systems which have the ability 
to deliver peptide bioactive agents to the upper small intestine region without any change in 
the bioactivity of the peptides. Wheat germ agglutinin helped in improving the intestinal 
residence time of the delivery system by binding with the specific carbohydrate moieties 
present in the intestinal mucosa. 
 
1.4.4 Thiolated polymers 
The presence of free thiol groups in the polymeric skeleton helps in the formation of 
disulphide bonds with that of the cysteine-rich sub-domains present in mucin which can 
substantially improve the mucoadhesive properties of the polymers e.g. poly (acrylic acid) 
and chitosan) in addition to the paracellular uptake of the bioactive agents. Various thiolated 
polymers include chitosan–iminothiolane, poly (acrylic acid)–cysteine, poly (acrylic acid)–
homocysteine, chitosan–thioglycolic acid, Chitosan–thioethylamidine, alginate–cysteine, 
poly (methacrylic acid)–cysteine and sodium carboxymethylcellulose–cysteine 
 
1.4.5 Lectin-based polymers 
Lectins are proteins which have ability to reversibly bind with specific sugar 
carbohydrate residues and are found in both animal and plant kingdom. The specific affinity 
of lectins towards sugar or carbohydrate residues provides them with specific cyto-adhesive 
property and is being explored to develop targeted delivery systems. Lectins extracted from 
legumes have been widely explored for targeted delivery systems.  
 
1.5 MICROSPHERES 
6,7 
Microspheres are spherical solid particles ranging in size from 1-1000 µm. They are 
spherical free flowing particles consisting of proteins or synthetic polymers which are 
biodegradable in nature. There are two types of microspheres; 
 Microcapsules 
 Micromatrices 
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Microcapsules are those in which entrapped substance is distinctly surrounded by distinct 
capsule wall and micromatrices in which entrapped substance is dispersing throughout the 
microspheres matrix. Solid biodegradable microspheres incorporating a drug dispersed or 
dissolved through particle matrix have the potential for the controlled release of drug. They 
are made up of polymeric, waxy, or other protective materials, that is, biodegradable 
synthetic polymers and modified natural products.  
1.6 TYPES OF MICROSPHERES 
1.6.1 Bioadhesive microspheres 
Adhesion can be defined as sticking of drug to the membrane by using the sticking 
property of the water soluble polymers. Adhesion of drug delivery device to the mucosal 
membrane such as buccal, ocular, rectal, nasal, etc can be termed as bio adhesion. This kind 
of microspheres exhibit prolonged residence time at the site of application and produces 
better therapeutic effect. 
1.6.2 Magnetic microspheres 
This kind of delivery system is very much important which localises the drug to the 
disease site. In this, larger amount of freely circulating drug can be replaced by smaller 
amount of magnetically targeted drug. Magnetic carriers receive magnetic responses to a 
magnetic field from incorporated materials that are used for magnetic microspheres like 
chitosan, dextran etc. 
 Therapeutic magnetic microspheres: Are used to deliver chemotherapeutic agent to 
liver tumour. Drugs like proteins and peptides can also be targeted through this 
system. 
 Diagnostic microspheres: Can be used for imaging liver metastasis and also can be 
used for distinguish bowel loops from other abdominal structures by forming nano 
size particles supramagnetic iron oxides. 
1.6.3 Floating microspheres. 
In floating types the bulk density is less than the gastric fluid and so remains 
buoyant in stomach without affecting gastric emptying rate. The drug is released slowly at 
the desired rate, if the system is floating on gastric content it increases gastric residence 
time and increases fluctuation in plasma concentration. Moreover it also reduces chances of 
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dose dumping and striking and produces prolonged therapeutic effect therefore reduces 
dosing frequencies. Drug (ketoprofen) given in this form. 
1.6.4 Radioactive microspheres 
Radio emobilisation therapy microspheres sized 0- 30 nm are of larger than 
capillaries and gets tapped in first capillary bed when they come across. They are injected to 
the arteries that lead to tumour of interest. Radioactive microspheres deliver high radiation 
dose to the targeted areas without damaging the normal surrounding tissues. It differs from 
drug delivery system, as radio activity is not released from microspheres within a 
radioisotope typical distance and the different kinds of radioactive microspheres are α 
emitters, β emitters, γ emitters. 
1.6.5 Polymeric microspheres 
The different types of polymeric microspheres can be classified as followed they are 
biodegradable polymeric microspheres and synthetic polymeric microspheres. 
1.6.5 (a) Biodegradable polymeric microspheres 
Natural polymers such as starch are used with the concept that they are 
biodegradable, biocompatible and also bioadhesive in nature. Biodegradable polymers 
prolongs the residence time when contact mucous membrane due to its high degree of 
swelling property with aqueous medium, results gel formation.  
The rate and extent of drug release is controlled by concentration of polymer and the 
release pattern in a sustained manner. The main drawback is in clinical use drug loading 
efficiency of biodegradable microspheres is complex and is difficult to control the drug 
release. 
1.6.5 (b) Synthetic polymeric microspheres 
The interest of synthetic polymeric microspheres are widely used in clinical 
application as bulking agent, fillers, embolic particles, drug delivery vehicles etc. and 
proved to be safe and biocompatible. But the main disadvantage of these kinds of 
microspheres, are tend to migrate away from injection site and lead to potential risk, 
embolism and further organ damage. 
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Microspheres are usually are polymers. They are classified into two types: 
 Synthetic Polymers 
 Natural Polymers 
Synthetic polymers are divided into two types. 
a) Non- biodegradable polymers 
Poly methyl acrylate (PMMA), Acrolein, Glycidyl methacrylate, Epoxy polymers. 
 
b) Biodegradable polymers 
Lactides, Glycolides& their copolymers, Poly alkyl cyanocrylates, Poly anhydrides  
Natural polymers obtained from different sources like proteins, carbohydrates and 
chemically modified carbohydrates. 
Proteins  : Albumins, Gelatin, Collagen 
Carbohydrates : Agarose, Carrageenan, Chitosan, Starch 
Chemically modified carbohydrates : Poly (acryl) dextran, Poly (acryl) starch 
Preparation of microspheres should satisfy certain criteria: 
1. The ability to incorporate reasonably high concentration of the drug. 
2. Stability of the preparation after synthesis with a clinically acceptable shelf life. 
3. Controlled particle size and dispersibility in aqueous vehicles for injection. 
4. Release of active reagent with a good control over a wide time scale. 
5. Biocompatibility with  a controllable biodegradability  
6. Susceptibility to chemical modification. 
1.7 METHOD OF PREPARATION
7 
1.7.1 Emulsion Solvent evaporation technique  
In this technique the processes are carried out in a liquid manufacturing vehicle. The 
microcapsule coating is dispersed in a volatile solvent which is immiscible with the liquid 
manufacturing vehicle phase. A core material to be microencapsulated is dissolved or 
dispersed in the coating polymer solution. With agitation the core material mixture is 
dispersed in the liquid manufacturing vehicle phase to obtain the appropriate size 
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microcapsule. The mixture is then heated if necessary to evaporate the solvent for the 
polymer of the core material is disperse in the polymer solution, polymer shrinks around the 
core. If the core material is dissolved in the coating polymer solution, matrix – type 
microcapsules are formed. The core materials may be either water soluble or water 
insoluble materials. Solvent evaporation involves the formation of an emulsion between 
polymer solution and an immiscible continuous phase whether aqueous (o/w) or non-
aqueous. 
 
 
 
 
Figure 2- Solvent evaporation technique 
 
1.7.2 Emulsion- Solvent Diffusion Technique 
In order to improve the residence time in colon floating micro particles of 
ketoprofen were prepared using emulsion solvent diffusion technique. The drug polymer 
mixture is dissolved in a mixture of ethanol and dichloromethane (1:1) and then the mixture 
is added drop wise to sodium lauryl sulphate (SLS) solution. The solution is stirred with 
propeller type agitator at room temperature at 150 rpm for 1 h. Thus the formed floating 
microspheres were washed and dried in a dessicator at room temperature. The following 
micro particles were sieved and collected. 
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1.7.3 Emulsion Cross linking Method 
In this method drug is dissolved in aqueous gelatine solution which is previously 
heated for 1 h at 40°C. The solution is added drop wise to liquid paraffin while stirring the 
mixture at 1500 rpm for 10 min at 35°C, results in w/o emulsion then further stirring is done 
for 10 min at 15°C. 
 The produced microspheres are washed respectively three times with acetone and 
isopropyl alcohol which then air dried, dispersed in 5mL of aqueous glutaraldehyde 
saturated toluene solution at room temperature for 3 h cross linking and then treated with 
100ml of 10 mm glycerine solution containing 0.1% w/v tween 80 at 37°C for 10 min to 
block unreacted glutaraldehyde. 
1.7.4 Multiple emulsion method
 
Multiple emulsion method involves formation of (o/w) Primary emulsion (non 
aqueous drug solution in polymer solution) and then addition of primary emulsion to 
external oily phase to form o/w/o emulsion followed by either addition of cross linking 
agent (glutaraldehyde) and evaporation of organic solvent.  
 
Multiple emulsion method of preparation is ideal for incorporating poorly aqueous 
soluble drug, thus enhancing its bioavailability. 
 
 
 
Figure 3- Multiple emulsion technique 
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1.7.5   Co-acervation method 
This process is based on the principle of decreasing the solubility of the polymer in 
organic phase to affect the formation of polymer rich phase called the coacervates. In this 
method, the drug particles are dispersed in a solution of the polymer and an incompatible 
polymer is added to the system which makes first polymer to phase separate and engulf the 
drug particles. Addition of non-solvent results in the solidification of polymer. Polylactic 
acid (PLA) microspheres have been prepared by this method by using butadiene as 
incompatible polymer. The process variables are very important since the rate of achieving 
the coacervates determines the distribution of the polymer film, the particle size and 
agglomeration of the formed particles. The agglomeration must be avoided by stirring the 
suspension using a suitable speed stirrer since as the process of microspheres formation 
begins the formed polymerize globules start to stick and form the agglomerates. Therefore 
the process variables are critical as they control the kinetic of the formed particles since 
there is no defined state of equilibrium attainment. 
 
1.7.6 Spray drying technique 
In Spray drying, the polymer is first dissolved in a suitable volatile organic solvent 
such as dichloromethane, acetone, etc. The drug in the solid form is then dispersed in the 
polymer solution under high-speed homogenization. This dispersion is then atomized in a 
stream of hot air. The atomization leads to the formation of the small droplets or the fine 
mist from which the solvent evaporate instantaneously leading the formation of the 
microspheres in a size range 1-100μm. Microparticles are separated from the hot air by 
means of the cyclone separator while the trace of solvent is removed by vacuum drying. 
One of the major advantages of process is feasibility of operation under aseptic conditions. 
This process is rapid and this leads to the formation of porous microparticles. 
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Figure 4- Spray drying technique 
 
1.7.7 Ionic gelation  
Alginate/ chitosan particulate system for diclofenac sodium release is prepared using 
this technique.25% (w/v) of diclofenac sodium is added to1.2 % (w/v) aqueous solution of 
sodium alginate. In order to get the complete solution stirring is continued and after that it is 
added drop wise to a solution containing Ca
2+
/ Al
 3+ 
chitosan solution in acetic acid. 
Microspheres which were formed were kept in original solution for internal gelification 
followed by filtration for separation. The complete release is obtained at pH 6.4-7.4 but the 
drug did not release in acidic pH. 
1.7.8 Hydroxy appatite (HAP) microspheres in sphere morphology 
This method is used to prepare microspheres with peculiar spheres in sphere 
morphology microspheres were prepared by o/w emulsion followed by solvent evaporation. 
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At first o/w emulsion is prepared by dispersing the organic phase (Diclofenac sodium 
containing 5%w/w of EVA and appropriate amount of HAP) in aqueous phase of surfactant. 
The organic phase is dispersed in the form of tiny droplets which were surrounded by 
surfactant molecules; this prevented the droplets from co solvencing and helped them to as 
stay individual droplets. While stirring the DCM is slowly evaporated and the droplets 
solidify individually to become microspheres. 
1.8 ENTRAPMENT OF DRUG IN MICROSPHERES
8 
 
The active component can be loaded by means of the physical entrapment, chemical 
linkage and surface absorption. The entrapment largely depends on the method of 
preparation and nature of the drug or polymer. The loading is carried out in pre-formed 
microspheres by incubating them with high concentration of the drug in a suitable solvent. 
 
1.9 DRUG RELEASE KINETICS FROM MICROSPHERES
8 
 
Release of the active constituent is an important consideration in case of 
microspheres. Many theoretically possible mechanisms may be considered for the release of 
drug from the microparticulates. 
 
1. Liberation due to polymer erosion or degradation, 
2. Self diffusion through the pore, 
3. Release from the surface of the polymer, 
4. Pulsed delivery initiated by the application of an oscillating or sonic field. 
 
The release profile from the microspheres depends on the nature of the polymer used 
in the preparation as well as on the nature of the active drug. The release of drug from both 
biodegradable as well as non biodegradable microsphere(s) is influenced by structure or 
micro-morphology of the carrier and the properties of the polymer itself. The drugs could be 
released through the microspheres by any of the three methods,  
 
I. The osmotically driven burst mechanism,  
II. Pore diffusion mechanism and  
III. By erosion or the degradation of the polymer.  
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In osmotically driven burst mechanism, water diffuses into the core through 
biodegradable or non biodegradable coating, creating sufficient pressure that ruptures the 
membrane. The burst effect is mainly controlled by three factors the macromolecule/ 
polymer ratio, particle size of the dispersed macromolecule and the particle size of the 
microspheres.  
 
The pore diffusion method is named so because as penetrating waterfront continue to 
diffuse towards the core. The dispersed protein/drug dissolves creating a water filled pore 
network through which the active principle diffuses out in a controlled manner. In case of 
the biodegradable polymers, the release is controlled by both the erosion as well as 
diffusion process. 
 
The polymer erosion, i.e. loss of polymer is accompanied by accumulation of the 
monomer in the release medium. The erosion of the polymer begins with the changes in the 
microstructure of the carrier as water penetrates within it leading to the plasticization of the 
matrix. This plasticization of the matrix finally leads to the cleavage of the hydrolytic 
bonds. The cleavage of the bond is also facilitated by the presence of the enzyme 
(lysozymes) in the surroundings.  
 
The erosion of the polymer may be either surfacial or it may be bulk leading to the rapid 
release of the drug active components. The rate and extent of water uptake therefore 
determines release profile of the system and depends on type of the polymer, porosity of the 
polymer matrix, protein drug loading etc. 
 
1.10 FACTORS AFFECTING THE RELEASE
 8 
 
Controlled release is an attainable and desirable characteristic for drug delivery 
systems. The factors affecting the drug release rate revolve around the structure of the 
matrix where the drug is contained and the chemical properties associated with both the 
polymer and the drug. 
 
Conventional oral delivery is not rate controlled. A drug encapsulated in a slowly 
degrading matrix provides the opportunity for slower release effects, but polymer 
degradation is not the only mechanism for the release of a drug. The drug release is also 
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diffusion controlled as the drug can travel through the pores formed during sphere 
hardening. In some cases, drugs containing nucleophilic groups can cause increased chain 
scission of the polymer matrix, which also increases the rate of drug expulsion. Polymer 
molecular weight, drug distribution, polymer blending, crystallinity and other factors are 
important in manipulating release profiles. 
 
1.11 FACTORS AFFECTING THE RELEASE FROM THE PARTICULATE 
SYSTEM
 8 
DRUG 
 Position in microspheres  
 Molecular weight 
 Physicochemical properties 
 Concentration 
 Interaction with matrix 
 
MICROSPHERES 
 Type of  the matrix polymer 
 Amount of the matrix polymer  
 Size and density of the microspheres  
 Extent of cross linking 
 Denaturation or polymerization 
 Adjuvant 
 
 
ENVIRONMENT 
 pH 
 Polarity 
 Presence of enzyme 
 
1.12. SUITABLE DRUG CANDIDATES FORMICROSPHERES DRUG DELIVERY
8 
 
Various drugs have their greatest therapeutic effect when released at the targeted 
area of body, particularly when the release is prolonged in a continuous, controlled manner. 
Drugs delivered in this manner have a lower level of side effects and provide their 
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therapeutic effects without the need for repeated dosages or with a low dosage frequency. 
Sustained release in the stomach is also useful for therapeutic agents that the stomach does 
not readily absorb, since sustained release prolongs the contact time of the agent in the 
stomach or in the other part of the body, which is where absorption occurs and contact time 
is limited. Appropriate candidate for microsphere drug delivery system is that 
 
a) Drugs that possess narrow absorption window in GI tract. e.g., riboflavin, levodopa. 
b) Drugs that act locally in the stomach. e.g., antacids and misoprostol.  
c) Drugs having poor bioavailability. 
 
1.13 RELEASE TYPE OF MICROSPHERES
 8 
 
A] Reservoir type system 
Release from the reservoir type system with rate controlling membrane proceeds by 
first penetration of the water through the membrane followed by dissolution of the drug in 
the penetrating dissolution fluid. The dissolved drug after partitioning through the 
membrane diffuses across the stagnant diffusion layer. The release is essentially governed 
by the Fick's first law of diffusion. 
 
B] Matrix system: 
Release profile of the drug from the matrix type of the device critically depends on 
the state of drug whether it is dissolved or dispersed in the polymer matrix. In the case of 
the drug dissolved in the polymeric matrix, amount of drug, and the nature of the polymer 
(whether hydrophobic or hydrophilic) affect the release profile. 
 
1.14 ROUTE TARGETING
 8 
I. Oral route 
The controlled release systems have been developed for oral administration. Oral 
route is also suggested for the delivery of the soluble antigens. The risk of dose dumping is 
minimized with this formulation, the smaller sized and high drug loaded particles show 
faster release. 
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II. Intranasal route 
In this type of targeting, the microspheres are given at the surface of nasal mucosa 
by considering the mucocilliary clearance. The particle size range of microspheres for 
targeting the respiratory tract is given table no. 1. 
 
Table 1- Particle size of the microspheres for targeting of specific area 
 
 
 
 
III. Ocular route 
The eye and the cornea are easily accessible targets. The washout effect, however, 
presents difficulties in retention of micro particulate drug carrier in the corneal sac. The 
rapid conversion of the particulate suspension to gel form reportedly leads to their longer 
retention in the eye. 
 
 
 
 
 
 
 
 
Respiratory  Required Particle size (µm) 
Nose 25-30 
Throat 20-28 
Pharynx 20-24 
Larynx 15-20 
Trachea 10-15 
Bronchi 8-12 
Bronchioles 8-10 
Alveolar duct 5-8 
Alveoli 4-8 
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1.15 CHARACTERIZATION PARAMETERS & METHODS
 8 
 
Microspheres are characterized in the following given parameters: 
 
Table 2-Parameters & method for microspheres characterization 
 
 
S.No 
 
Characterizations Parameters 
 
Method 
 
1 
 
Particle size and  shape 
 
Light microscopy& SEM 
 
2 
 
Chemical analysis 
 
Electron  Spectroscopy 
 
3 
 
Degradation of polymer 
 
FTIR 
 
4 
 
Density 
 
Pychnometer 
 
5 
 
Determination of  isoelectric point 
 
Micro electrophoresis 
 
6 
 
Surface Carboxylic Acid Residue 
 
Radioactive glycine 
 
7 
 
Surface amino acid residue 
 
Radioactive 14c acetic acid 
conjugate. 
 
8 
 
Capture efficiency 
 
UV spectroscopy 
 
9 
 
Release study 
 
USP basket  apparatus 
 
10 
 
Flow property 
 
Angle of contact 
 
 
1.16 APPLICATIONS
 7 
1) Medical Applications 
 Release of proteins, hormones and peptides over extended period of time. 
 Gene therapy with DNA plasmids and also delivery of insulin. 
 Vaccine delivery for treatment of diseases like hepatitis, influenza, pertusis, 
ricin toxoid, diphtheria, birth control. 
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 Passive targeting of leaky tumour vessels, active targeting of tumour cells, 
antigens by intraarterial/ intravenous application. 
 Tumour targeting with doxorubicin and also treatments of leishmaniasis. 
 Magnetic microspheres can be used for stem cell extraction and bone marrow 
purging. 
 Used in isolation of antibodies, cell separation and toxin extraction by affinity 
chromatography. 
 Used for various diagnostic tests for infectious diseases like bacterial, viral, 
and fungal. 
 
2) Radioactive Microsphere’s Applications 
 
 Can be used for radioembolisation of liver and spleen tumours. 
 Used for radiosynvectomy of arthiritis joint, local radiotherapy, interactivity 
treatment. 
 Imaging of liver, spleen, bone marrow, lung and thrombus in deep vein 
thrombosis. 
 
3) Other Applications 
 
 Fluorescent microspheres can be used for membrane based technologies for 
flow cytometry, cell biology, microbiology, Fluorescent Linked Immuno-
Sorbent Assay. 
 Yttrium 90 can be used for primary treatment of hepatocellular carcinoma. 
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2. REVIEW OF LITERATURE 
 Behera BC et al16 .prepared Glipizide loaded polymethacrylate microspheres by solvent 
evaporation method.The mean particle size ranged from 400-660µm and the 
encapsulation efficiencies ranged from 40.27-86.67%. 
 
 Mukul Sengupta et al17.formulated and evaluated ethyl cellulose microspheres of 
Glipizide by solvent evaporation method. 
 
 Arora Neha et al18. evaluated the entrapment efficiency of Glipizide microspheres. The 
percentage entrapment efficiency of eudragit coated Glipizide microspheres with and 
without plasticizers diisobutylpthalate and dioctylpthalate were observed. The increase 
in concentration of polymer entrapment efficiency was studied. 
 
 Shailesh Lokhande et al19. developed Glipizide containing microballoons for floating 
controlled drug delivery system. The microballoons were prepared by emulsion solvent 
diffusion method using enteric acrylic polymer dissolved in a mixture of 
dichloromethane and ethanol. 
 
 Gaikwad Abhijit et al20. designed the Glipizide pellets using fluid bed coating method; 
Drug loaded pellets were coated with dispersion of Eudragit NE 30 D : Eudragit 230 D 
55(80:20) upto 30% weight gain. The shape and surface morphology by scanning 
electron microscopy and it shows uniformity in the coating process.The prepared pellets 
exhibited prolonged drug release (˃12 h) by altering the theoretical weight gain of 
pellets. 
 
 Sarode SM et al21. formulated floating microspheres of Glipizide by emulsion solvent 
diffusion technique.The percentage drug entrapment was found to be 91%. Buoyancy of 
microspheres was found to be more than 40% with 12 h floating capacity. 
 
 Cristina Pirvu22. evaluated the process of Xantinol nicotinate release from 
unreticulated and for differently reticulated gelatin microspheres.An increase in the 
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microspheres size was correlated with a decrease of both the swelling and the drug 
release rates and proposed a diffusional model for the delivery of xantinol nicotinate. 
 
 Suja C Jayan et al23.designed gelatin microspheres of Salbutamol sulphate by Co-
acervation phase separation method and characterized by optical microscope and 
scanning electron microscopy. The percentage drug entrapment wasupto 80% and 
microspheres sustained the drug release over a period of 8.5 h. 
 
 Jeevana et al24. prepared and evaluated gelatin microspheres of Tramadol 
hydrochloride by single emulsion technique with entrapment efficiency of 97.2%, drug 
release for 12 h and maximum drug release of 99.79%. 
 
 Ohta et al25. Generated Cisplatin-conjugated gelatin microspheres (GMSs) and to 
confirm the subsequent release of cisplatin invitro. The GMSs (1mg) were immersed in 
50µl of a cisplatin solution (0.06, 0.15, 0.27, 0.30 or 0.54 mg ml-1) at 38˚C to allow 
conjugation. The platinum concentration in the GMSs samples was investigated as a 
function of the concentration of cisplatin solution used in their preparation, number of 
immersions in cisplatin (1, 2, 3, 4 or 5) and the period of immersion in proportion to the 
concentration of cisplatin solution and the length or number of immersions in cisplatin 
invitro release tests demonstrate that the release rate (%) from GMSs after 1, 3, 6, 12 or 
24 h was 4.8, 5.5, 7.6, 10,0 and 12.4 respectively. 
 
 Wakode R et al26. prepared gelatin mcrospheres for topical delivery of Vitamin A 
palmitate. Gelatin microspheres were prepared using Co-acervation method and process 
was optimized using 23 factorial designs. Drug loaded microspheres were incorporated 
in carbopol gel for controlled delivery for 24 h. The drug entrapment 67% was achieved 
with gelatin: drug (1:2). Drug release from microspheres followed Higuchi kinetics 
while formulation showed zero order release profile. 
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 Chauhan MK et al27. evaluated the effect of natural crosslinker on release of gelatin 
microspheres loaded with Flurbiprofen. Gelatin microspheres crosslinked with different 
percent of crosslinker(0.25, 0.5, 1%) were prepared.The results suggested that the 
degree of crosslinking increased with increased concentration of Genipin and 
consequently retard the release of drug from the gelatin microspheres. 
 
 Rahisuddin et al28. studied the effect of stabilizing solvent on the preparation of 
Nimesulide loaded gelatin microspheres. The gelatin microspheres were prepared by 
emulsion cross linking technique with glutaraldehyde as cross linking agent using 
various stabilizing agents like sesame oil, liquid paraffin and soybean oil. The 
entrapment efficiency and drug release were maximum with nimesulide. 
 
 Leucuta SE et al29. developed Nifedipine embedded in a gelatin matrix to develop a 
prolonged release dosage form. The effects of polymer/drug ratio, size of the beads, 
crosslinking with formaldehyde and ethylcellulose coating of the gelatin microspheres 
on the invitro release rate of the drug were investigated.The invitro release kinetics of 
nifedipine from gelatin microspheres were mainly first-order; from formaldehyde 
hardened gelatin microspheres, complied with the diffusion model for a spherical 
matrix, and from coated gelatin microspheres, obeyed zero-order kinetics. On 
administration of a single oral dose of nifedipine-loaded hardened gelatin microspheres 
to volunteers, suggest that the preparation can be considered as a sustained release 
delivery system for nifedipine. 
 
 Maria Angela Vandelli et al30. hypothesis suggested gelatin microspheres treated by 
micro-waves 250˚C for 10 min can be easily loaded with drug by soaking process 
avoiding drug degradation. 
 
 Huang-Chien Liang et al31. Evaluated Genipin-crosslinked gelatin microspheres as a 
drug carrier for intramuscular administration and performed invitro and invivo studies. 
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 Sivakumar M et al32. prepared composite microspheres from bioactive ceramics such 
as coralline hydroxyapatite [CHA, Ca10 (Po4)6(OH )2 ] granules and gelatin by the 
dispersion polymerization and the Gentamicin was incorporated by the absorption 
method. The particle size found to be 16mm. The thermal behavior of composite 
microspheres was studied using thermogravimetric analysis and differential scanning 
calorimetric analysis. The cumulative in vitro release profile of gentamicin from 
composite microspheres showed near zero order patterns. 
 
 Chowdary KPR et al33.studied on the invitro and invivo evaluation of ethyl cellulose 
microspheres of Glipizide prepared by an industrially feasible emulsion-solvent 
evaporation technique and microspheres were investigated. These microspheres were 
found suitable for parenteral controlled release. 
 
 Mustafa SK et al34. studied on the formulation of controlled release Glipizide pellets 
using pan coating method. The surface morphologies and the cross sectional 
investigations were evaluated in the polarizing light microscope. As a result the coated 
pellet formulations were found to yield of glipizide between 8 to 13 h. 
 
 Chowdary KPR et al35. studied on the drug and invitro and invivo evaluation of 
mucoadhesive microcapsules of Glipizide for oral controlled release. 
Microencapsulation has been accepted as a process to achieve controlled release and 
drug targeting. The study is to develop characterize and evaluate mucoadhesive 
microcapsules of glipizide employing various mucoadhesive polymers for prolonged 
gastrointestinal absorption. 
 
 Senthil A et al36. developed chitosan loaded mucoadhesive microspheres of Glipizide 
for treatment of type 2 diabetes mellitus. Both invitro and invivo evaluations were 
carried out. Microspheres were prepared by simple emulsification technique. 
 
 Uma Mahesh et al37.formulatedgelatin microspheres containing Diclofenac sodium by 
Co-acervation phase separation procedure using different drug, gelatin and HPMC ratio. 
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Microspheres with low amount of gelatin and high amount of HPMC showed prolonged 
action in in vitro dissolution studies. 
 
 
 Ofokonsi KC et al38. formulated and evaluated microspheres based on Gelatin- Mucin 
admixtures for the rectal delivery of Cefuroxime Sodium by emulsification cross 
linking method. The inclusion of S-mucin in the composition of microspheres has an 
enhancer effect on the release rectal bioavailability of Cefuroxime sodium. 
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3. RATIONALE OF THE STUDY 14,15 
 
Drug delivery systems that can precisely control the release rates have an enormous 
impact on the healthcare system. The controlled release DDS are mainly aimed at controlling 
the rate of drug delivery and sustaining the duration of therapeutic activity. Drug release from 
these systems should be at a desired rate, predictable and reproducible. Amongst the various 
approaches for oral controlled DDS, mucoadhesive microspheres have generated much interest 
among researchers around the world, due to its increased GI transit time.  
 
The drug of choice, Glipizide, is an effective anti -diabetic drug particularly in Type II 
Diabetes (Non-insulin dependent diabetes mellitus). It is a second generation sulfonylurea that 
actually lowers the blood glucose level in human by stimulating the pancreatic cell and thereby 
releasing the insulin. It has a short biological half-life of 2-5 hours, which necessitates its 
administration in 2 or 3 doses of 2.5 to 20 mg14, to a maximum of 40 mg per day. Thus, the 
development of controlled release dosage form would be clearly advantageous. 
 
Gelatin, a natural polymer can be used for the preparation of microspheres by emulsion 
cross linking technique, because of its ability to increase its biological half life by adhering to 
the mucous membrane. 
 
 The present work was designed with an aim of formulating mucoadhesive microspheres 
of Glipizide using Gelatin as a biocompatible polymer for per-oral administration and to further 
evaluate the formulation characteristics, mucoadhesion properties and the release of glipizide 
from the resulting microspheres. 
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4. PLAN OF THE WORK 
4.1 Plan of Work: 
 
The present work is carried out to prepare and evaluate the microspheres Glipizide using 
Gelatin as polymer in various proportions. The following experimental protocol was therefore 
designed to allow a systemic approach to the study. 
 
 Preformulation studies 
 FTIR studies 
 Construction of standard calibration curve 
 Formulation of  Cross linked microspheres 
 Particle size analysis by microscopy 
 Shape, surface characterization 
 Percentage yield 
 Entrapment efficiency 
 Drug loading Capacity 
 Bulk density 
 True density 
 Hausner’s ratio 
 Compressibility index 
 Angle of repose 
 Swelling ratio 
 In vitro mucoadhesion study 
 In-vitro release study 
 Mechanism of release kinetics 
 Comparative study with marketed formulation 
 Stability study 
DISEASE PROFILE 2014 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, CHENNAI Page 28 
 
5. DISEASE PROFILE 
5.1 DIABETES MELLITUS
9,10,11,12 
Diabetes mellitus is a group of metabolic diseases characterized by elevated blood 
glucose levels(hyperglycemia) resulting from defects in insulin secretion, insulin action or 
both. Insulin is a hormone manufactured by the beta cells of the pancreas, which is required to 
utilize glucose from digested food as an energy source. Chronic hyperglycemia is associated 
with microvascular and macro vascular complications that can lead to visual impairment, 
blindness, kidney disease, nerve damage, amputations, heart disease, and stroke. In 1997 an 
estimated 4.5% of the US population had diabetes. Direct and indirect health care expenses 
were estimated at $98 billion.
 
 
 
Figure 5- Characterestics of Diabetes mellitus 
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    Diabetes mellitus is a metabolic disorder characterized by hyperglycaemia, glycosuria, 
hyperlipaemia, negative nitrogen balance and sometimes ketonaemia. A wide spread 
pathological changes is thickening of capillary basemen membrane, increase in vessel wall 
matrix and cellular proliferation resulting in vascular complications like lumen narrowing, early 
atherosclerosis, sclerosis of glomerular capillaries, retinopathy, neuropathy and peripheral 
vascular insufficiency. 
 
Two major types of diabetes mellitus are: 
5.1.1 TYPE I: Insulin Dependent Diabetes Mellitus (IDDM), juvenile onset of diabetes 
mellitus 
There is β-Cell destruction in pancreatic islets; majority of cases are autoimmune (type 
1A) antibodies that destroys β-Cells are detectable in blood, but some are idiopathic type (type 
1B) no β-cell antibody is found. In all type 1 case circulating insulin levels are low or very low, 
and patients are more prone to ketosis. This type is less common and has low degree of genetic 
predisposition. In type 1 diabetes, the body does not produce insulin, and daily insulin 
injections are required. Over 700,000 people in the United States have type 1 diabetes; this is 5-
10% of all cases of diabetes mellitus. 
 
 
Figure 6 - Type 1 Diabetes mellitus 
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5.1.2 TYPE II: Non Insulin Dependent Diabetes Mellitus (NIDDM), maturity onset 
diabetes mellitus 
There is no loss or moderate reduction in β-cell mass; insulin in circulation is low, 
normal or even high, no anti β-cell antibody is demonstrable; has a high degree of genetic 
predisposition; generally has late onset (past middle age). Over 90% cases are type 2 DM. 
Causes may be: 
 
 Abnormality in gluco-receptor of β-cells so that they respond at higher glucose 
concentration or relative β-cell deficiency. 
 Reduced sensitivity to peripheral tissues to insulin: reduction in number of insulin 
receptors, down regulation of insulin receptors. Many hypertensive’s are 
hyperinsulinaemic, but normoglycaemic; exhibit insulin resistance associated with 
dyslipidaemia (metabolic syndrome). Hyperinsulinaemia per sec has been implicated in 
causing angiopathy 
 Excess of hyperglycaemic hormones (glucagon, etc)/ Obesity cause relative insulin 
deficiency and the β-cells lag behind. 
 
 
 
 
 
 
 
 
 
Figure 7 - Causes for beta cell failure 
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Type 2 diabetes is the result of failure to produce sufficient insulin and insulin resistance. 
Elevated blood glucose levels are managed with reduced food intake, increased physical 
activity, and eventually oral medications or insulin.  
 
Type 2 diabetes is believed to affect more than 15 million adult Americans, 50% of whom are 
undiagnosed. It is typically diagnosed during adulthood. However with the increasing incidence 
of childhood obesity and concurrent insulin resistance, the number of children diagnosed with 
type 2 diabetes has also increased worldwide. 
 
5.1.3 Contributing factors 
 
– Obesity 
– Age (onset of puberty is associated with increased insulin resistance) 
– Lack of physical activity 
– Genetic predisposition 
– Racial/ethnic background (African American, Native American, Hispanic and    
   Asian/ Pacific Islander) 
– Conditions associated with insulin resistance (e.g., polycystic ovary syndrome) 
 
5.1.4 Outcomes 
Diabetes has significant associated morbidity and mortality. Patients with diabetes have 
a 2 to 4 fold increase in the risk of both cardiovascular and cerebrovascular disease, resulting in 
an increased mortality rate among patients with diabetes compared to the general population. 
Microvascular complications also occur including retinopathy, nephropathy and neuropathy 
and these can progress to the end-stage outcomes of blindness, renal failure and amputation.  
 Diabetes is the leading cause of new cases of blindness in adults ages 20-74 and the 
leading cause of end stage kidney disease in the U.S. seventy percent of non-traumatic lower 
extremity amputations occur in patients with diabetes. The morbidity and mortality of diabetes 
are higher for minorities than for Caucasians. 
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5.1.5 Screening 
 The American Diabetes Association (ADA) recommends that screening be considered 
at least at 3-year intervals beginning at age 45. Screening individuals with risk factors 
for diabetes should be considered at earlier ages. 
 Individuals with hypertension (>135/80) should be screened for diabetes (USPSTF level 
B recommendation). In adults who have hypertension and diabetes, lowering blood 
pressure below conventional target values reduces the incidence of cardiovascular 
events and cardiovascular mortality and justifies screening.  
 
 Screening may be reasonable for other at-risk subjects (e.g., those with obesity, history 
of gestational diabetes mellitus, family history, and high-risk ethnic minorities). Based 
on expert opinion the ADA recommends considering earlier or more frequent screening 
for those with other risk factors including family history, physical inactivity, minority 
ethnicity, previously identified impaired fasting glucose or impaired glucose tolerance, 
a history of HDL cholesterol ≤ 35 mg/dL, and/or a triglyceride level of ≥ 250 mg/dL, 
polycystic ovarian disease, or a history of vascular disease.  
 
 Women who have had gestational diabetes mellitus (GDM) should be screened for 
diabetes, as about 50% will have type 2 diabetes within 10 years. 
5.1.6 Treatment 
 Glucose Lowering Therapy 
It is best to treat type 2 diabetes as vigorously as possible to avoid or delay the 
long term consequences of elevated blood glucose levels, high blood pressure, and 
dyslipidemia. Treatment focuses on discovering the most effective method to lower 
blood glucose levels, whether it is lifestyle modifications, insulin therapy, oral agents, 
or any combination of these factors. The diabetes team must work with the teen and the 
family to educate them about the importance of good control and to make the necessary 
adjustments in treatment every 4-6 weeks until acceptable control is achieved. 
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• At diagnosis, teens with type 2 diabetes who are acutely ill with significant 
hyperglycemia (>300mg/dl) and ketosis require insulin therapy. Insulin 
regimens are similar to those for teens with type1 diabetes. In the less ill teen, 
initial treatment with medical nutrition therapy and exercise or glucose lowering 
oral agent may be appropriate. In both circumstances, target blood glucose goals 
are similar to those with type 1 diabetes and treatment recommendations may 
change depending on blood glucose control. 
 
• Glucose-lowering oral agents may be effective with type 2 diabetes. 
 
 
Figure 8 - Glucose lowering agents 
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 Sulfonylureas 
 
Sulfonylureas lower serum glucose by increasing insulin secretion. 
Sulfonylureas are traditionally used as first line agents in type 2 diabetes. 
Insulin secretagogues stimulate insulin secretion by interacting with the ATP-
sensitive potassium channel on the beta cells. These drugs are most effective in 
individuals with type 2 DM of relatively recent onset (<5 years), who have residual 
endogenous insulin production.  
First-generation sulfonylureas chlorpropamide, tolazamide, tolbutamide; have a 
longer half-life, a greater incidence of hypoglycemia, more frequent drug interactions, 
and are now rarely used.  
Second-generation sulfonylureas have a more rapid onset of action and better 
coverage of the postprandial glucose rise, but the shorter half-life of some agents may 
require more than once-a-day dosing.  
Sulfonylureas reduce both fasting and postprandial glucose and should be 
initiated at low doses and increased at 1 to 2 week intervals based on SMBG. In general, 
sulfonylureas increase insulin acutely and thus should be taken shortly before a meal; 
with chronic therapy, though, the insulin release is more sustained. Glimepiride and 
glipizide can be given in a single daily dose and are preferred over Glyburide.  
Repaglinide and nateglinide are not sulfonylureas but also interact with the 
ATP-sensitive potassium channel. Because of their short half-life, these agents are 
given with each meal or immediately before to reduce meal-related glucose excursions. 
For patients with any renal impairment, glipizide is preferred. Severe 
hypoglycemia can occur in patients with significant renal impairment. Patients are 
typically treated with a second-generation sulfonylurea starting at a low dose. Dose 
increments may be made every two weeks. 
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6. DRUG PROFILE
13 
IUPAC Name 
Glipizide is 1- cyclohexyl-3-[[4-2-[[5-methylpyrazine-2-yl) 
carbonyl]amino]ethyl]phenyl]sulphonyl]urea 
Chemical structure 
 
 
Molecular formula      C21H27N5O4S 
Molecular weight          445.5g/mol 
BCS Classification        Class-2 (High Permeability & low solubility)  
 
Description                 A white or almost white, crystalline powder 
Solubility                       Practically insoluble in water, sparingly soluble in acetone 
                                        and soluble in methylene chloride ( Dichloromethane), chloroform, 
                                       dimethyl formamide. 
Dose                               5-20 mg twice or once daily  
Category                       Oral hypoglycaemic agent 
Mode of action    Mechanism of action is produced by partially blocking potassium 
                                       channels in the β cells of islets of langerhans.  
Contra indications    Glipizide is contraindicated in patients with 
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  Known hypersensitivity to glipizide or any excipients in GIT tablets 
  Type 1 Diabetes, diabetic ketoacidosis with or without coma. This  
  condition should be treated with insulin. 
Pharmacokinetic  
Properties   Duration: 12-24 h. 
 
 Absorption: Rapid and complete; delayed with food.  
 
 Distribution: 10-11 L. 
 
 Protein binding: 98% to 99%; primarily to albumin. 
 
    Time to peak: 1-3 h; Extended release 6-12 h. 
Adverse Effects 
 With conventional tablets: Nausea, anorexia, vomiting, asthenia, head ache, pain, 
dizziness, pyrosis gastralgia, diarrhoea and constipation. 
 With extended-release tablets: Asthenia, headache, pain, dizziness, nervousness, 
tremor, diarrhoea, hypoglycemia and flatulence.  
 Glipizide in fixed combination with metformin hydrochloride: Upper respiratory 
tract infection, diarrhoea, dizziness, hypertension, nausea/vomiting, musculoskeletal 
pain, headache, abdominal pain and urinary tract infection. 
Special Populations 
 Renal or hepatic impairment may increase serum glipizide concentrations and 
reduce elimination.  
 Severe renal impairment may decrease the renal excretion and increase the terminal 
elimination half-life of glipizide metabolites. 
Storage 
Tablets (conventional) 
Tight, light-resistant containers at a temperature <30°C. 
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Tablets (extended-release) 
 Store at 15–30°C. 
 Protect from moisture and humidity. 
Interactions for Glipizide 
Drug Interaction 
Alcohol Rarely, disulfiram like reactions 
Antifungals Increased plasma concentrations of glipizide and hypoglycemic 
effect 
Anticoagulants, oral Glipizide could displace or be displaced by oral anticoagulants 
from plasma protein binding sites 
β-Adrenergic blocking 
agents 
Impaired glucose tolerance; increased frequency or severity of 
hypoglycemia and hypoglycemia-induced complications 
Calcium-channel 
blocking agents 
May exacerbate diabetes mellitus 
Chloramphenicol Increases hypoglycemic effect 
Cimetidine Inhibits the hepatic metabolism of glipizide and potentiate 
hypoglycemic effect 
Contraceptives, oral May exacerbate diabetes mellitus 
Corticosteroids May exacerbate diabetes mellitus 
Diuretics, thiazide May exacerbate diabetes mellitus 
Estrogens May exacerbate diabetes mellitus 
Hydantoins Glipizide could displace or be displaced by hydantoins from 
plasma protein binding sites 
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Isoniazid May exacerbate diabetes mellitus 
MAO inhibitors Increases hypoglycemic effects 
Niacin May exacerbate diabetes mellitus 
 
NSAIDs Glipizide could displace or be displaced by nonsteroidal anti-
inflammatory agents from plasma protein binding sites 
Phenothiazines May exacerbate diabetes mellitus 
Phenytoin May exacerbate diabetes mellitus 
Probenecid Increases hypoglycemic effects 
Rifampin May exacerbate diabetes mellitus 
Salicylate Does not displace salicylate from plasma protein binding sites 
Sulfonamides Glipizide could displace or be displaced by sulfonamides from 
plasma protein binding sites 
Sympathomimetic agents May exacerbate diabetes mellitus 
Thyroid agents May exacerbate diabetes mellitus 
Actions 
 Sulfonylurea anti-diabetic agent.  
 Lowers blood glucose concentration in diabetic and non-diabetic individuals. 
 Stimulates secretion of postprandial endogenous insulin from the beta cells of the 
pancreas.  
 During prolonged administration, extrapancreatic effects such as enhanced 
peripheral sensitivity to insulin occur and reduction of basal hepatic glucose 
production may contribute to the hypoglycemic action. 
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7. POLYMER PROFILE13 
BP                         Gelatin 
Synonyms             Byco;  Crysogel; E441; gelatin; instagel; kolatin; solugel; vitagel. 
Chemical name    Gelatine [9000-70-8] 
Empirical formula and molecular weight 
Gelatin is a generic term for a mixture of purified protein fractions obtained either by 
partial acid hydrolysis (type A gelatin) or by partial alkaline hydrolysis (type B gelatin) of 
animal collagen. Gelatin may also be a mixture of both types. 
The protein fractions consist almost entirely of amino acids joined together b amide 
linkages form linear polymers, varying in molecular weight from 2000 – 200000. 
Functional category 
Coating agent; Film forming agent; Gelling agent; Suspending agent; Tablet binder; 
Viscosity- increasing agent. 
Description 
Gelatin occurs as a light-amber to faintly yellow-colored, vitreous, brittle solid. It is 
practically odorless and tasteless and is available as translucent sheets, flakes and granules, or 
as a coarse powder. 
Solubility 
Practically insoluble in acetone, chloroform, ethanol(95%), ether, and methanol. 
Soluble in glycerin, acids and alkalis. Strong acids or alkalis cause precipitation. In water, 
gelatin swells and softens, gradually absorbing between 5 to 10 times its own weight of water. 
Gelatin is soluble in water above 40˚C, forming a colloidal solution, which gels on cooling to 
35–40˚C. This gel–sol system is thixotropic and heat reversible, the melting temperature being 
slightly higher than the setting point; the melting point can be varied by the addition of 
glycerin. 
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Pharmaceutical applications 
 Gelatin is widely used in a variety of pharmaceutical formulations, including its use as a 
biodegradable matrix material in an implantable delivery system. 
 It is used to form either hard or soft gelatin capsules. 
 Low-molecular-weight gelatins are used to enhance the dissolution of orally ingested 
drugs. 
 Gelatin used in the preparation of pastes, pastilles, pessaries and suppositories. 
 It is used as a tablet binder and coating agent and as a viscosity-increasing agent for 
solutions and semisolids. 
 Therapeutically, gelatin has been used in the preparation of wound dressings and has 
been used as a plasma substitute. 
 Absorbable gelatin is available as sterile film, ophthalmic film, sterile sponge, sterile 
compressed sponge and sterile powder from sponge. 
 Gelatin sponge has haemostatic properties. 
 Gelatin is also widely used in food products and photographic emulsions. 
MATERIALS AND METHODS 2014 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, CHENNAI Page 41 
 
8. MATERIALS AND METHODS 
8.1. LIST OF DRUGS AND EXCIPIENTS 
The list of drugs and excipients, their manufacturer and use in the present study are 
shown in Table 3 
Table 3 - List of drugs and excipients 
 Name of the material  Name of the company  Use in the formulation 
Glipizide Arvind Remedies, Chennai Active  Ingredient 
Gelatin type B Bafna Pharma, Chennai Polymer 
Liquid Paraffin Merck Laboratories, Mumbai Dispersion phase 
Glutaraldehyde Merck Laboratories, Mumbai Cross linking agent 
Span 80 Merck Laboratories, Mumbai Stabilising agent 
Sodium hydroxide IRP ,Chennai Reagent 
Potassium dihydrogen ortho 
phosphate 
Merck Laboratories, Mumbai Reagent 
Petroleum Benzene 
 60 -80˚ C 
Nice Laboratories, Cochin Solvent 
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8.2 EQUIPMENTS 
Table 4- Equipments used in the formulation and evaluation of Microspheres 
 Name of the equipment Name of the company 
Magnetic stirrer Remi, India 
Electronic Balance Asha Scientific Company, Mumbai 
UV Spectrophotometer Shimadzu, Japan 
Hot air oven Industrial heaters, Chennai 
Centrifuge Remi Equipments, India 
Light microscope Focus Trademark, India 
Overhead stirrer Remi, India 
Sonicator Lark, India 
SEM Analyser Hitachi  S-3400, Japan 
FT-IR Spectrophotometer Nicolet, India 
Dissolution Apparatus Veego, Mumbai 
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8.3 PREFORMULATION STUDIES 39 
The preformulation studies are the first step in the rational development of any formulation. 
It can be defined as “investigation of physical and chemical properties of  drug substance alone 
and combined with the excipients “.The overall objective of preformulation testing is to 
generate information useful to the formulator in developing stable and bioavailable dosage 
forms that can be mass produced. The goals of the study are, 
 
 To establish physical characteristics. 
 To establish its compatibility with the excipients. 
 To determine kinetic rate profile. 
 
8.4 DRUG – POLYMER COMPATIBILITY STUDIES 
8.4.1 Fourier Transform Infra Red Spectroscopy40 
The compatibility between pure drug and polymer was detected by FT-IR spectra 
obtained .1-2 mg of glipizide alone, mixture of drug and polymer were weighed and mixed 
properly with potassium bromide uniformly. The spectra’s were recorded over the wave 
number 4000-500cm-1. 
Table 5- Composition of drug and excipients for FTIR spectra 
                 S.No                Ingredients 
1. Drug 
2. Gelatin 
3. Drug + Gelatin mixture 
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8.5 CALIBRATION CURVE FOR GLIPIZIDE41 
8.5.1 Preparation of pH 7.4 Phosphate Buffer 
An accurately measured 50ml of 0.2 M potassium dihydrogen orthophosphate was 
transferred to a 200ml volumetric flask and 39.14ml of 0.2M sodium hydroxide was added to it. 
Volume was made up to 200ml with distilled water, mixed and pH was adjusted to 7.4 with 
0.2M sodium hydroxide or 0.2M orthophophoric acid.  
 
8.5.2 Preparation of 0.2 M Potassium Dihydrogen Phosphate 
An accurately weighed 27.21g of monobasic potassium dihydrogen phosphate was 
dissolved in 1000ml of distilled water and mixed.  
 
8.5.3 Preparation of 0.2 M Sodium Hydroxide Solution 
An accurately weighed 8g of sodium hydroxide pellets were dissolved in 1000ml of 
distilled water and mixed. 
8.5.4 Standard Curve in Phosphate Buffer pH 7.4 
An accurately weighed amount of 100 mg of Glipizide was transferred into a volumetric 
flask and volume was made up to 100 ml with 7.4 pH phosphate buffer. The resulted solution 
had the concentration of 1mg/ml which was labelled as stock solution 1. From this stock 
solution 10 ml was taken and diluted to 100ml with 7.4 pH phosphate buffer which was given 
the solution having the concentration of 100µg/ml which was labelled as stock 2. 
Necessary dilutions were made by using second solution to give the different 
concentration of glipizide2-10µg solutions can be made. 
The volumetric solution 10µg/ml was scanned in a UV-Visible double beam 
spectrophotometer to determine the λ max of the drug. The absorbance of the volumetric 
solution was recorded at λmax of 223nm and plotted graphically to the standard graph of 
glipizide. 
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8.6 PREPARATION CROSS LINKED GLIPIZIDE LOADED 
GELATINMICROSPHERES 42,43,44 
Gelatin microspheres were prepared by an emulsification cross linking method. 10 ml 
of 15% (w/v) aqueous gelatin solution preheated to 60˚C. The specified quantity of Glipizide 
was dissolved in phosphate buffer pH 7.4 preheated to 60˚C. Then the mixture was added drop 
wise to 50 ml of liquid paraffin with 1% w/v span 80 preheated to 60˚C and emulsified by 
stirring with magnetic stirrer at rpm 1000. Then the stabilized emulsion is allowed to cool and 
cross linking agent glutaraldehyde was added and the stirring was continued at room 
temperature for 6 hours. The cross linked microspheres were cooled and washed with 
Petroleum benzene to remove unreacted glutaraldehyde and liquid paraffin. After washing, the 
microspheres were dried at room temperature and stored in dessicator. 
Table 6-Formulation table 
Batch No Glipizide 
(mg) 
Gelatin (g) Liquid 
Paraffin(ml) 
Glutaraldehyde(ml) Drug: 
Polymer 
ratio 
F1 100 2.0 50 0.5 1:20 
F2 100 1.5 50 0.5 1:15 
F3 100 1 50 0.5 1:10 
F4 100 0.75 50 0.5 1:7.5 
F5 100 0.5 50 0.5 1:5 
F6 100 0.25 50 0.5 1:2.5 
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8.7 EVALUATION OF MICROSPHERES44 
8.7.1 Percentage Yield 
 
The total amount of dried microcapsules was weighed and the percentage yield was 
calculated by taking into consideration the total weight of the drug and polymer used for 
preparation of microspheres.  
 
                                     Practical yield 
Percentage Yield =                                    x 100  
                                   Theoretical yield  
 
8.7.2 Estimation of Drug Content 
100 mg of microspheres was weighed and suspended in phosphate buffer pH 7.4. The 
suspension was suitably diluted with phosphate buffer pH 7.4 in 100 ml standard flask and 
filtered to separate the fragments. Drug content was analyzed after suitable dilution by UV 
spectrophotometer at a wavelength of 223 nm against phosphate buffer pH 7.4 as blank. All the 
studies were carried out in triplicate. 
 
8.7.3 Entrapment Efficiency (EE) 
 
50 mg of microspheres were powdered and dissolved in phosphate buffer pH 7.4 in 50 
ml volumetric flask and made up to the volume. The solution was kept for 1 hour with 
occasional shaking. Further 1 ml solution was diluted up to 50 ml with phosphate buffer pH 
7.4. The content was analyzed spectrophotometrically at 223 nm against phosphate buffer pH 
7.4 as blank. The % EE of each formulation was calculated using the following equation 
 
 
 
 
                    Actual Drug Content  
% EE =                                                x 100  
                 Theoretical Drug Content 
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8.7.4 Drug Loading Capacity 48 
Drug loaded microspheres were digested with phosphate buffer pH 7.4 at room 
temperature for 12 h. After filtration and suitable dilution, Glipizide present in the solution was 
determined. 
 
                                   Actual drug content in weighed quantity of powder
 
 Drug loading (%) =                                                                                            × 100 
                                           Weighed quantity of the microspheres  
 
8.7.5 Particle Size Analysis 45 
Particle size analysis was carried out by using optical microscopy. About 200 
microspheres were selected and their size was determined by using optical microscope fitted 
with standard micrometer scales. All the studies were carried out in triplicate. 
 
8.7.6Scanning Electron Microscope 44 
Morphological examination of the surface of microspheres was performed using a 
scanning electron microscope (SEM) (Hitachi S-3400, Japan). The sample was sputtered with 
gold and the observations were made under vacuum. 
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8.8 EVALUATION OF FLOW PROPERTIES45,46,47 
Flow properties of microspheres were investigated by determining by following 
standard procedures. All studies were carried out in triplicate (n=3). 
 
8.8.1Bulk Density  
Bulk density was determined by taking a known weight of dried microspheres in a 
measuring cylinder and tapping 3 times from 1 inch height at 2 second interval. The bulk 
volume is noted and the bulk density was calculated from the following equation.  
 
                             Weight of microspheres 
Bulk density =   
                           Bulk volume of microspheres 
 
8.8.2Tapped Density 
Tapped density is the ratio of mass of microspheres to the volume occupied by the same 
mass of the powder after a standard tapping of a measure. Weighed quantity of microspheres 
was taken in a cylinder and tapping 300 times from 1 inch at 2 second interval. The tapped 
volume is noted and the tapped density was calculated from the following equation 
 
                               Weight of microspheres  
Tapped density =  
                                   Tapped volume  
 
8.8.3Hausner’s Ratio 
 
Hausner’s ratio is used for predicting the flow characteristics. 
 
                                Tapped density 
Hausner’s ratio = 
                                  Bulk density 
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8.8.4Compressibility Index 
 
Compressibility index was determined by using bulk density and tapped density. 
 
                                               Tapped density – Bulk density 
Compressibility index (%) =                                                       × 100 
                                                        Tapped density 
 
 
Table 7 - Compressibility index table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compressibility   
index(%) 
Hausner’s 
ratio 
Angle of 
repose 
(degrees) 
Type of flow 
 
< 10 
 
1.00-1.11 
 
25–30 
 
Excellent 
 
11-15 
 
1.12-1.18 
 
31–35 
 
Good 
 
16-20 
 
1.19-1.25 
 
36–40 
 
Fair 
 
21-25 
 
1.26-1.34 
 
41–45 
 
Passable 
 
26-31 
 
1.35-1.45 
 
46–55 
 
Poor 
 
32-37 
 
1.46-1.59 
 
56–65 
 
Very poor 
 
>38 
 
>1.60 
 
>66 
 
Very very poor 
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8.8.5Angle of Repose  
A funnel was fixed to a stand and bottom of the funnel was fixed at a height of 3 cm 
from the plane. Microspheres were placed in funnel and allowed to flow freely and the height 
and radius of the heap of microspheres was measured. 
 
                                         tan θ = h /r  
 
 
Where, ‘h’ is the height of heap and  
 ‘r’ is the radius of heap of microspheres. 
 
8.9 SWELLING RATIO48 
50 mg of microspheres was placed in a glass vial containing 10ml of phosphate buffer 
of pH 7.4 at 37± 0.5˚C in incubator with occasional shaking. The microspheres were 
periodically removed, blotted with filter paper and their changes in weights were measured 
during the swelling equilibrium was attained. Finally, the weight of the swollen microspheres 
was recorded after a period of 4 h and the swelling index was calculated from the formula. The 
studies were carried in triplicate. 
 
                               (W
e
– W
o
)  
Swelling Ratio = 
                                     W
e
 
 
Where, W
o
is the initial weight of microspheres and 
W
e
is the weight of the swollen microspheres at equilibrium with swelling medium at 
time‘t’.  
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8.10 IN VITRO MUCOADHESIONSTUDY49 
The microspheres were placed on the sheep intestinal mucosa after fixing to the 
polyethylene support. The mucosa was then placed in the dessicator to maintain at ˃ 80% RH 
at room temperature at 30 min to allow the polymer to hydrate and to prevent drying of the 
mucus. The mucosa was then observed under a microscope and the number of particles 
attached to the particular area was counted. After 30 minutes, the polyethylene support was 
introduced into a plastic tube cut in circular manner and held in an inclined position at an angle 
of 45˚. Mucosa was washed thoroughly at flow rate of 1 ml min-1 for 5 min with phosphate 
buffer pH 7.4. Tissue was again observed under a microscope to see the number of 
microspheres remaining in the same field area. The adhesion number was determined by the 
following equation 
 
Na =N/No × 100 
 
Where, Na is adhesion number, 
 No is total number of particles in a particular area and   
N is number of particles attached to the mucosa after washing. 
 
8.11 IN-VITRO DRUG RELEASE STUDY50 
In-vitro drug release studies were performed using USP dissolution test apparatus I 
(basket type). The dissolution studies were performed in 900 ml dissolution medium 
(Phosphate buffer pH 7.4), at 50 rpm maintained at 37 ± 0.5ºC. At predetermined time intervals 
an aliquot of 10 ml was withdrawn and replenished with fresh medium. Amount of drug in each 
aliquot was determined using a UV-Spectrophotometer (UV-1800, Shimadzu, Japan) at 223 nm 
using a suitable blank. All trials were conducted in triplicate and the average (± SD) reading 
was noted. 
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8.12RELEASE MECHANISM51,52 
Experimental data were fit to following kinetic equation to determine the order and mechanism 
of drug release.
 
 
Zero order equation  
C =kot 
 
First order equation  
Log C = Log C0 kt / 2.303 
 
Higuchi’s square root model  
Q = Kt√t 
 
Where, ´Q
t
´is amount of drug released at a time‘t’,  
Q
o
is the initial amount of drug in the dissolution medium, 
k, K, K
HC
are release constants.  
 
Hixson Crowell cube root law  
Q01/3 – Qt1/3 =KHCt 
 
Korsemeyer-Peppas empirical power law  
Mt / M
∞ 
= K tn
 
 
Where, M
t
/M
∞
is the fraction of drug released at a time‘t’,  
K is the Korsemeyer release constant and ‘n’ characterizes the mechanism of drug 
release from formulations during diffusion process 
.  
n = 0.45 for case I or Fickian diffusion, n ˂ 0.5 for anomalous or non- Fickian diffusion, 
n = 1 for case II transport and n ˂ 1 for super case II transport. 
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8.13 COMPARATIVE STUDY WITH MARKETED SAMPLE 23 
In-vitro drug release studies were performed using USP dissolution test apparatus I 
(basket type). The dissolution studies were performed in 900 ml dissolution medium 
(Phosphate buffer pH 7.4), at 50 rpm maintained at 37 ± 0.5ºC. At predetermined time intervals 
an aliquot of 10 ml was withdrawn and replenished with fresh medium. Amount of drug in each 
aliquot was determined using a UV-Spectrophotometer (UV-1800, Shimadzu, Japan) at 223 nm 
using a suitable blank. All trials were conducted in triplicate and the average (± SD) reading 
was noted. 
The invitro drug release in phosphate buffer pH 7.4 for the optimized formulation was 
compared with the marketed sample using a similar procedure (SR tablet). 
 
8.14 STABILITY STUDY53 
From the prepared microspheres the formulation which showed optimum drug content 
and percentage release was selected for stability studies. The optimized formulation were 
placed in borosilicate screw capped glass containers and stored at a temperature of (40±2° C / 
75% RH) for a period of 90 days. The samples were assayed for drug content at regular 
intervals of 30th, 45th and 90th day. 
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9. RESULTS AND DISCUSSION 
9.PREFORMULATION STUDIES 
9.1 Drug-Polymer Compatibility Studies 
9.1.1 FTIR Spectroscopy 
The compatibility between drug and polymer was confirmed by using FTIR 
spectroscopy. 
Infrared spectroscopic analysis for drug (Glipizide), Gelatin, Drug-gelatin mixture was 
carried out.  
The principal IR peaks of pure Glipizide and Gelatin are shown in table 8 
Table 8- FTIR spectrum interpretation 
 
Sample 
 
Characteristics bands 
 
Possible Functionalities 
 
Glipizide 
 
3000-3700 cm
-1 
2700-3300 cm
-1 
1650-1700 cm
-1 
1650-1700 cm
-1 
1334-1442 cm
-1 
1157 cm
-1 
650-900 cm
-1 
 
 
NH- Stretching 
C-H stretching 
C=O stretching 
-CONH stretching 
C-H bend (Cyclohexane) 
S=O stretching 
C-H bend (Benzene) 
 
Gelatin 
 
1689 cm
-1 
1527 cm
-1
 
1157 cm
-1 
 
 
C=O stretching vibrations 
N-H  bending vibrations 
C-N  stretching vibrations 
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FTIR Spectra of Glipizide 
 
Figure 9 
 
FTIR Spectra of Gelatin 
 
Figure 10 
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FTIR Spectra of Physical Mixture 
 
Figure 11 
 
 
FTIR Spectra of Optimized Formulation 
 
Figure 12 
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Inference  
The peaks observed in the FTIR spectrum of physical mixture and optimized 
formulation showed no shift and no disappearance of characteristic peaks of drug as well as 
polymer. This suggests that there is no interaction between the drug and polymer. Hence it can 
be concluded that the drug maintain its identity without undergoing any chemical interaction 
with Gelatin. 
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9.2 STANDARD CALIBRATION CURVE FOR GLIPIZIDE 
The UV spectrophotometric method was used to standardize Glipizide at a wavelength 
of 223 nm. The standard graph was constructed using phosphate buffer pH 7.4.  
Table9-Standard Curve for Glipizide 
Concentration 
(µg/ml) 
Absorbance 
 
0 
 
0 
 
2 
 
0.123 
 
4 
 
0.230 
 
6 
 
0.338 
 
8 
 
0.452 
 
10 
 
0.565 
 
 
Figure 13- Standard graph of Glipizide in phosphate buffer pH 7.4 
Inference  
As shown in figure the linearity was exhibited at a concentration range of 0 – 100 µg/ml 
of Glipizide. It obeys Beer-Lambert’s law. 
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9.3 EVALUATION OF MICROSPHERES  
9.3.1 Percentage Yield 
Table 10- Percentage yield 
 
Formulation  
 
Theoretical yield 
(g) 
 
Practical yield (g) 
 
Percentage yield 
(%) 
 
F1 
 
2.1 
 
1.950 
 
92.85 
 
F2 
 
1.6 
 
1.447 
 
90.43 
 
F3 
 
1.1 
 
1.057 
 
96.09 
 
F4 
 
0.850 
 
0.797 
 
93.76 
 
F5 
 
0.600 
 
0.576 
 
96 
 
F6 
 
0.350 
 
0.280 
 
80.14 
 
After the preparation of microspheres practical yield and percentage yield were 
calculated. It was found that percentage yield was in the range of 80.14 % to 92.85 % 
 
Figure 14- Percentage yield 
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9.3.2 Drug Content 
The drug content was found in the range of 81 to 87.35% w/w. 
Table 11-Drug content 
 
Formulation 
 
Drug content (%) w/w 
 
F1 
 
81.76 
 
F2 
 
85.75 
 
F3 
 
87 
 
F4 
 
83.20 
 
F5 
 
87.35 
 
F6 
 
82.84 
 
 
 
Figure 15- Drug content 
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9.3.3 Entrapment Efficiency 
The results of entrapment efficiency of the microspheres are given in table 12. 
Table 12- Entrapment efficiency 
 
Formulation 
 
Entrapment Efficiency (%) 
 
F1 
 
81 
 
F2 
 
86.25 
 
F3 
 
87 
 
F4 
 
83.25 
 
F5 
 
87.5 
 
F6 
 
82 
 
The percentage entrapment efficiency calculated for all microspheres ranged from 81 to 87.5 
%. The highest entrapment efficiency is found for the formulation F5. 
 
 
Figure 16- Entrapment efficiency 
76
78
80
82
84
86
88
F1 F2 F3 F4 F5 F6
E
n
tr
a
p
m
en
t 
E
ff
ic
ie
n
cy
 
Formulation  
ENTRAPMENT EFFICIENCY 
RESULTS AND DISCUSSION 2014 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, CHENNAI Page 62 
 
9.3.4 Drug Loading Capacity 
The drug loading capacity of the microspheres was found to be in the range 3.893 to 
17.56%. 
Table 13- Drug loading Capacity 
 
Formulation 
 
Drug loading Capacity (%) 
 
F1 
 
3.893 
 
F2 
 
5.358 
 
F3 
 
7.56 
 
F4 
 
10.23 
 
F5 
 
17.56 
 
F6 
 
12.39 
 
 
 
Figure 17- Drug loading Capacity 
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9.3.5 Mean Particle Size by Microscopy 
The particle size was found in the range of 520 to 752µm. 
Table 14 - Mean Particle size  
 
Formulation  
 
Mean Particle Size (µm) 
 
F1 
 
587 
 
F2 
 
570 
 
F3 
 
642 
 
F4 
 
693 
 
F5 
 
752 
 
F6 
 
525 
 
 
 
 
Figure18- Mean Particle Size of Microspheres 
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9.3.6 Scanning Electron Microscopy 
Morphological analysis of the microspheres was carried out using optical microscopy 
and scanning electron microscopy (SEM). 
 
 
 
Figure 19- SEM Photographs of optimized formulation F5 
 
Inference 
The SEM photograph reveals that the microspheres were discrete and almost spherical   
in shape. The particle size was found below 500µm. 
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9.4 EVALUATION OF FLOW PROPERTIES 
Table 15- Flow Properties of Glipizide microspheres 
 
 
 
 
 
 
 
 
Formulation 
 
Bulk 
density(g/ml) 
 
Tapped 
density(g/ml) 
 
Angle of 
repose(˚) 
 
Compressibilityind
ex(%) 
 
Hausner’s ratio 
 
F1 
 
0.6±0.154 
 
0.75±1.125 
 
26.46± 3.3894 
 
20± 1.25 
 
1.25±0.1857 
 
F2 
 
0.625±2.15 
 
0.714±1.84 
 
26.83± 0.3412 
 
12.46± 2.01 
 
1.142±0.2103 
 
F3 
 
0.7±1.267 
 
0.8±2.54 
 
24.61± 1.456 
 
12.5±1.01 
 
1.142±0.9577 
 
F4 
 
0.627±0.145 
 
0.718±0.115 
 
28.82± 1.270 
 
12.47±1.78 
 
1.143±0.1245 
 
F5 
 
0.7±2.12 
 
0.777±0.255 
 
26.2±2.8202 
 
9.09±1.23 
 
1.11±0.2134 
 
F6 
 
0.71±0.850 
 
0.83±1.12 
 
25.54± 2.3810 
 
12.36±0.9997 
 
1.141±0.3988 
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9.4.1 Bulk Density 
The bulk density was found in the range of 0.6 to 0.71 g/ml. 
 
 
Figure 20- Bulk density 
 
9.4.2 Tapped Density 
The tapped density was found in the range of 0.14 to 0.88 g/ml. 
 
Figure 21- Tapped density 
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9.4.3 Hausner’s Ratio 
The Hausner’s ratio of the formulations were found in the range of 1.11 to 1.42. 
 
 
Figure 22- Hausner’s ratio 
 
9.4.4 Compressibility Index(%) 
The Compressibility index was found in the range of 9.09 to 20 %. 
 
Figure 24-Compressibility index 
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9.4.5 Angle of Repose 
The angle repose was found in the range of 25.54 to 28.8˚. The flow property of the 
microspheres was found to be good. 
 
 
Figure 24 - Angle of repose 
 
Inference 
The flow properties of the formulated microspheres were evaluated. The flow  property 
was found to be good. 
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9.5 SWELLING RATIO  
The results of swelling studies of the microspheres are given in table 14. 
Table 16- Swelling ratio 
 
Time in 
hours 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
1 
 
0.8 
 
0.6 
 
0.714 
 
0.94 
 
0.78 
 
0.96 
 
2 
 
1.4 
 
1.04 
 
1.5 
 
1.54 
 
1.64 
 
1.38 
 
3 
 
1.9 
 
1.96 
 
2 
 
2 
 
2.2 
 
2 
 
4 
 
1.9 
 
1.96 
 
2 
 
2 
 
2.2 
 
2 
 
5 
 
1.9 
 
1.96 
 
2 
 
2 
 
2.2 
 
2 
 
 
Figure 25- Swelling ratio 
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9.6 IN VITRO MUCOADHESION STUDY 
Table 17- In vitro mucoadhesion study 
 
 
  Time 
(hours) 
 
% Microspheres adhered 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
0.5 
 
92.67±1.15 
 
94±2.00 
 
 
94±2.00 
 
90.67±2.0 
 
95.33±1.15 
 
91.33±1.15 
 
1 
 
86.66±1.15 
 
 
87.33±3.06 
 
86±2.00 
 
82.67±1.15 
 
88±2.00 
 
81.33±1.15 
 
2 
 
76.67±1.15 
 
 
81.33±3.06 
 
78.67±2.31 
 
70±2.00 
 
82.67±1.15 
 
74.67±2.31 
 
3 
 
70.01±2.00 
 
72.67±2.3 
 
 
68.67±1.15 
 
60.67±1.15 
 
75.33±1.15 
 
57.33±1.15 
 
4 
 
56.67±1.15 
 
60.67±1.15 
 
 
54±2.00 
 
44.67±1.25 
 
64±2.00 
 
40±2.00 
 
5 
 
43.33±1.15 
 
46±2.00 
 
 
38.67±1.15 
 
33.33±2.01 
 
49±4.16 
 
28.6±1.15 
 
 
Figure 26-Invitro mucoadhesion study 
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9.7 IN VITRO RELEASE STUDY 
Table 18 – Cumulative percentage drug release of Formulation F1 to F6 
Time 
(hours) 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
1 9.88 5.89 9.74 7.29 9.24 9.24 
2 18.24 12.1 13.81 15.18 14.55 17.8 
3 24.51 17.88 20.2 21.21 24.47 23.21 
4 31.51 23.41 27.22 27.85 30.6 31.29 
5 37.72 27.86 30.92 36.72 36.8 38.25 
6 45.72 34.3 39.75 42.99 45.01 41.56 
7 52.07 38.22 44.15 49.29 48.75 52.01 
8 79.32 44.9 50.86 57 58.39 58.3 
9 86.25 50.67 59.33 61.52 63.57 65.55 
10 93.03 55.59 63.89 71.94 71.4 69.94 
11 100.75 67.37 67.37 76.6 75.06 74.77 
24  74.22 89.65 98.88 100.3 97.7 
 
 
 
Figure 27-In vitro Drug Release Study of Formulations F1- F6 
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9.8.1 In vitro evaluation study of F5 formulation (1:5) 
The in vitro drug release results are given below 
Table 19 - In vitro drug release 
 
S.No 
 
Time in hours 
Cumulative 
% drug release 
1 1 5.89 ± 1.035407 
2 2 12.10 ± 1.00307 
3 3 17.88 ± 1.01444 
4 4 23.81 ± 0.61822 
5 5 27.86 ± 0.42129 
6 6 34.30 ± 0.27108 
7 7 38.22 ± 0.82890 
8 8 44.9± 0.6468 
9 9 50.67± 0.80155 
10 10 55.59± 0.72997 
11 11 67.37± 0.60942 
12 12 70.01± 0.59211 
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Figure 28-In vitro Drug Release Study of Formulation F6 
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9.9 RELEASE KINETICS AND MECHANISM 
The kinetics of drug release for optimized Glipizide loaded gelatin microspheres F5 in 
phosphate buffer pH 7.4 Table 19 
Table 20- Mechanism of release kinetics 
 
Time 
(hours) 
 
Cumulativ
e % drug 
release 
 
%Cumulativ
e drug 
remaining 
 
Log% 
Cumulative 
drug 
remaining 
 
Square 
root of 
time 
 
Log 
time 
 
Log% 
cumulative 
drug release 
 
Cube root 
of % drug 
remaining 
 
0 
  
0 0 
 
100 
 
2.000 
 
0 
 
α 
 
α 
 
4.6415 
 
1 
 
5.89 
 
94.11 
 
1.9736 
 
1 
 
0 
 
0.7701 
 
4.5486 
 
2 
 
12.10 
 
87.9 
 
1.9439 
 
1.4142 
 
0.3010 
 
1.0827 
 
4.446 
 
3 
 
17.88 
 
82.12 
 
1.9144 
 
1.7320 
 
0.4771 
 
1.2523 
 
4.3465 
 
4 
 
23.41 
 
76.59 
 
1.8841 
 
2 
 
0.6020 
 
1.3694 
 
4.2467 
 
5 
 
27.86 
 
72.14 
 
1.8581 
 
1.236 
 
0.6989 
 
1.4449 
 
4.1628 
 
6 
 
34.30 
 
65.7 
 
1.7572 
 
2.4494 
 
0.7781 
 
1.5352 
 
4.0351 
 
7 
 
38.22 
 
61.78 
 
1.7908 
 
2.6457 
 
0.845 
 
1.5822 
 
3.953 
 
24 
 
75.06 
 
24.94 
 
1.1368 
 
4.898 
 
1.3802 
 
1.8754 
 
2.9216 
 
28 
 
99.17 
 
0.83 
 
1.2623 
 
5.2915 
 
1.4471 
 
1.9963 
 
0.9397 
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Figure 29- Zero order kinetics for Optimized Formulation F5 
 
 
 
Figure 30 - First order kinetics for Optimized Formulation F5 
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Figure 31- Higuchi diffusion kinetics for Optimized Formulation F5 
 
 
 
Figure 32-KorsemeyerPeppas Equation for Optimized Formulation F5 
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Figure 33-Hixson Crowell Cube root plot for Optimized Formulation F5 
 
 
 The order of drug release was found to be zero order, in which regression value was 
0.997. 
 The ‘n’ value of Korsemeyer Peppas equation was found to be 0.998. From this it was 
concluded that the drug release follows a non-fickinian diffusion. 
Inference 
Drug can be released from microspheres by the mechanism of diffusion. It was 
observed that the mechanism governing the release of Glipizide from gelatin based drug 
delivery system is predominantly drug diffusion. 
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9.10 COMPARATIVE STUDY WITH MARKETED SAMPLE 
The results of the comparative study for SR tablet and optimized formulation F5 in 
phosphate buffer pH 7.4 are given in the table 18. 
Table 21- Comparison study of Marketed SR tablet with Optimized formulation 
 
 
Time in hours 
 
% Cumulative drug release 
of SR Tablet 
 
% Cumulative drug release 
of Optimized formulation 
 
1 
 
8.69  ± 0.61384 
 
5.89 ± 1.035407 
 
2 
 
16.10 ± 0.98266 
 
12.10 ± 1.00307 
 
3 
 
23.23 ± 1.1172 
 
17.88 ± 1.01444 
 
4 
 
30.52 ± 0.62933 
 
23.81 ± 0.61822 
 
5 
 
37.88 ± 0.5309 
 
27.86 ± 0.42129 
 
6 
 
46.42 ± 0.6153 
 
34.30 ± 0.27108 
 
7 
 
51.31 ± 1.60852 
 
38.22 ± 0.82890 
 
24 
 
101.57 ± 0.8890 
 
75.06 ± 0.59211 
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Figure 34- Comparison of Marketed SR with Optimized Formulation F5 
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9.11 STABILITY STUDY 
Stability study was carried out for the F5 formulation by exposing it to a temperature 40 
± 2 C/ 75% RH for 3 months. The sample was analyzed for drug content at the regular 
intervals. It was found that no remarkable change in the drug content of  F5 formulation. This 
indicates that F5 was stable for following temperature. 
 
Table 22-Stability study data for F5 formulation 
 
  S.No 
 
       Days 
% Drug content      
          (w/w) 
40± 2° C/ 75%RH 
 
1. 
 
0 
 
87.35 ± 00 
 
2. 
 
30 
 
81.32 ± 0.041 
 
3. 
 
45 
 
87.18 ± 0.036 
 
4. 
 
90 
 
87.12 ± 0.02 
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10. SUMMARY 
• An attempt was made to formulate glipizide loaded microspheres using Gelatin as a 
mucoadhesive polymer by emulsion cross linking method using 25%v/v glutaraldehyde 
as a cross linking agent for management of type 2 diabetes mellitus. 
• The literature survey reveals that extensive research has been carried out on 
development of mucoadhesive microspheres containing anti-diabetic drug by various 
methods. It is noteworthy that there was no literature review available describing the 
formulation of glipizide loaded mucoadhesive microspheres prepared using Gelatin 
hence the study was further preceded. 
• In the present study, F1, F2, F3, F4, F5 and F6 formulations were prepared using gelatin 
as a polymer (1:20, 1:15, 1:10, 1:7.5, 1:5 and 1:2.5) in six different ratios. The effect of 
polymer as well as decreasing concentration of gelatin on microspheres was studied by 
subjecting all the formulations to various evaluation parameters. 
• The FTIR study was carried out for the drug, polymer, physical mixture and optimized 
formulation F5. In FTIR study, all characteristic peaks in the spectra appeared without 
any remarkable changes showing that there is no chemical interaction between the drug 
and polymer used in the preparation of microspheres.  
• The mean particle size study was carried out by using microscopic analysis and found 
that the range for all formulations was varied from 525 to 792 µm due to change in drug 
and polymer ratio. 
• The morphology of optimized formulation was studied by SEM analysis and found that 
shape of microspheres were spongy, discrete, almost spherical and found to be 
satisfactory. 
• The drug content for all the formulations was found to be in the range of 81 to 87% 
w/w. The formulation F5 had the highest drug content of 87% w/w. 
• The entrapment efficiency of all formulations was found to be in the range of 81 to 
87.35%. The entrapment efficiency of formulation F5 was found to be higher. 
• The drug loading was found to be in the range 3.58 to 17.5%.The formulation F5 had 
the maximum loading efficiency. 
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• All the microsphere formulations showed equilibrium swelling ratio in the range of 1.9 
to 2.2. The formulation F5 had the swelling ratio of 2.2 at the end of 5 h. 
• The in vitro mucoadhesion study was conducted for all the formulations and the results 
were found in the range of 28.6 to 49%. The results revealed that the formulation F5 
had 49% mucoadhesion at the end of 5h. 
• The in vitro drug release study was carried out for all the formulations and the 
formulation F5 (1:5) showed sustained release of 75.06% at the end of 24 h. 
• The results of in vitro drug release studies showed that the drug release was found to be 
retarded by increasing the polymer ratio. 
• The in vitro release study results were applied to various kinetics models to predict the 
mechanism of drug release.  
• The release rate followed zero order kinetics and good linearity was found with Higuchi 
diffusion kinetics. 
• In Korsemeyer Peppas equation, the n value was greater than 0.5 indicating anomalous 
diffusion or non- fickian diffusion may be the mechanism of release. 
• The in vitro drug release in pH 7.4 for optimized formulation was compared with the 
marketed glipizide sustained release tablets and the results showed that the microsphere 
formulation had a sustained release of 75.06% when compared to marketed sustained 
release tablet 101.57% at the end of 24 h.  
• Results suggest that formulation F5 prepared using drug: polymer ratio 1:5 showed 
good entrapment efficiency, sustained drug release and satisfactory mucoadhesion as 
compared to other formulations, so it was further subjected to the accelerated stability 
study. 
• The formulation F5 was stable at the tested storage condition (40± 2˚C/75%RH) up to 3 
months. No significant changes were observed in the drug content at the end of 3 
months. 
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11. CONCLUSION 
The mucoadhesive microspheres of Glipizide were prepared by Emulsion cross linking 
method using natural polymer Gelatin utilizing temperature change and cross linking agent 
glutaraldehyde was able to sustain the drug release efficacy. 
By varying the drug: polymer concentration ratio, the drug release was sustained. 
The evaluation parameters like morphological analysis, drug content, entrapment 
efficiency, drug loading capacity, swelling ratio, in vitro mucoadhesion studies and invitro drug 
release studies was done for the microspheres and found to be satisfactory. 
The stability study results shows that the formulation F5 was stable at temperature 40 ± 
2˚C/75% RH at the end of 3 months. 
The comparative study with the marketed SR formulation results showed that the F5 
microsphere formulation had a sustained and prolonged drug release at the end of 24 h than the 
marketed glipizide SR formulation. 
The results of the study revealed that the use of natural polymer Gelatin is an effective 
strategy for the designing and development of glipizide loaded mucoadhesive microspheres for 
easy, reproducible and effective oral controlled drug delivery for the treatment of type  II 
Diabetes mellitus. 
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